Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

TerminatedOBSERVATIONAL
Enrollment

199

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Rheumatoid ArthritisCrohn's Disease
Trial Locations (45)

Unknown

12, Kazan'

16, Kazan'

11, Moscow

14, Moscow

24, Moscow

25, Moscow

31, Moscow

34, Moscow

36, Moscow

40, Moscow

42, Moscow

45, Moscow

5, Moscow

7, Moscow

8, Moscow

9, Moscow

20, Orenburg

21, Orenburg

29, Orenburg

43, Perm

39, Petrozavodzk

19, Saint Petersburg

1, Saint Petersburg

3, Saint Petersburg

4, Saint Petersburg

6, Saint Petersburg

15, Samara

18, Samara

41, Samara

33, Saratov

17, Shakhty

10, Taganrog

26, Tolyatti

22, Ufa

27, Ufa

32, Ufa

35, Ufa

37, Ufa

38, Ufa

55, Ufa

30, Ulyanovsk

23, Veliky Novgorod

2, Yaroslavl

13, Yekaterinburg

28, Yekaterinburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT01577264 - Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD) | Biotech Hunter | Biotech Hunter